Prediction of Sarcopenia Onset in Older Adults with Diabetes using Urinary Titin Levels: A Japanese Cohort Study

TL;DR

This study shows that high urinary titin levels predict sarcopenia in older adults with diabetes, offering a noninvasive way to identify those at risk.

Contribution

The study demonstrates urinary titin's predictive power for sarcopenia in older adults with type 2 diabetes.

Findings

High urinary titin levels were linked to increased sarcopenia risk (HR per SD: 1.38).

Elevated titin levels also correlated with low muscle strength (HR per SD: 1.37).

Risk estimates were consistent across various subgroups, including BMI and HbA1c levels.

Abstract

Standardized biomarkers for incident sarcopenia are still elusive. Recently, we reported that urinary titin serves as a novel, noninvasive biomarker to identify individuals with diabetes at a high risk of muscle damage and sarcopenia (Tanabe, et al. Diabetes Care in press). However, the predictive power of urinary titin for sarcopenia has not yet been clarified in older adults. In Japanese older adults with type 2 diabetes, baseline urinary titin levels were measured, and sarcopenia was evaluated annually using the Asian Working Group for Sarcopenia (AWGS) 2019 criteria. Kaplan-Meier curves, Cox models, and time-dependent receiver operating characteristic analyses were employed to assess incident sarcopenia. Among the 287 participants (median follow-up: 824 days), 39 developed sarcopenia. The high titin tertile was associated with an elevated sarcopenia risk (log-rank P = 0.008) and low muscle strength (P = 0.004). Cox models associated titin with sarcopenia (adjusted hazard ratio per SD: 1.38, 95% CI: 1.07–1.78, P = 0.013) and low muscle strength (HR per SD: 1.37, 95% CI: 1.10–1.70, P = 0.005). Risk estimates were consistent across subgroups, including males, individuals with BMI< 25 kg/m2, HbA1c ≥7%, and eGFR ≥60 mL/min/1.73 m2 (P for interaction >0.05). Elevated urinary titin levels predict sarcopenia and low muscle strength in older adults with type 2 diabetes, supporting its use as a noninvasive biomarker in this population.